Organon
OGNApprovedOrganon is a publicly traded, diversified healthcare company that emerged as a spin-off from Merck & Co. (known as MSD outside the U.S. and Canada) in June 2021. The company's portfolio is built around three core pillars: a leading women's health franchise, a growing portfolio of biosimilars, and a stable of established brands across various therapeutic areas. With a global commercial footprint and a commitment to addressing unmet needs, particularly in women's health, Organon aims to drive sustainable growth through its existing portfolio, pipeline development, and strategic business development.
OGN · Stock Price
Historical price data
AI Company Overview
Organon is a publicly traded, diversified healthcare company that emerged as a spin-off from Merck & Co. (known as MSD outside the U.S. and Canada) in June 2021. The company's portfolio is built around three core pillars: a leading women's health franchise, a growing portfolio of biosimilars, and a stable of established brands across various therapeutic areas. With a global commercial footprint and a commitment to addressing unmet needs, particularly in women's health, Organon aims to drive sustainable growth through its existing portfolio, pipeline development, and strategic business development.
Technology Platform
Commercial and development expertise in Women's Health and Biosimilars, focusing on late-stage development, in-licensing, and global commercialization rather than early-stage discovery technology.
Pipeline Snapshot
483483 drugs in pipeline, 278 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified) | Exercise-induced Bronchoconstriction (EIB) | Approved |
| desloratadine | Rhinitis, Allergic, Seasonal | Approved |
| Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate) + Crea... | Dermatitis, Atopic | Approved |
| losartan potassium + Comparator: Placebo | High Blood Pressure | Approved |
| Ezetimibe + Placebo + Atorvastatin 10 mg | Hypercholesterolemia | Approved |
Funding History
1FDA Approved Drugs
36Opportunities
Risk Factors
Competitive Landscape
Organon competes with large pharma like Bayer and Pfizer in Women's Health, and with biosimilar specialists like Amgen and Celltrion. Its differentiation lies in its dedicated focus on women's health, a balanced portfolio of growth and cash-generating assets, and a global commercial infrastructure.
Company Info
Trading
Contact
Therapeutic Areas
Sectors
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile